Cocrystal Pharma
COCP
42 hedge funds and large institutions have $25M invested in Cocrystal Pharma in 2021 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 6 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 6
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
85% more capital invested
Capital invested by funds: $13.5M → $25M (+$11.5M)
20% more funds holding
Funds holding: 35 → 42 (+7)
0.57% more ownership
Funds ownership: 1.14% → 1.71% (+0.57%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$7.74M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.48M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.45M |
| 4 |
ACM
Altium Capital Management
New York
|
+$983K |
| 5 |
State Street
Boston,
Massachusetts
|
+$348K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$2.1M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$63.6K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$60K |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$25.3K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$24K |
COCP Hedge Fund Activity: Q2 2021 in Review
42 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q2 2021, worth a combined $25M — up 85% from $13.5M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new COCP positions and 6 closed out — a net gain of 7 holders — while 15 added to existing stakes and 6 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $7.74M. The largest seller was Renaissance Technologies, cutting an estimated $2.1M.
- 42 institutional investors held Cocrystal Pharma (COCP) as of Q2 2021, up from 35 in Q1 2021.
- Funds reported $25M of Cocrystal Pharma stock for Q2 2021, up 85% quarter-over-quarter.
- 13 funds opened new Cocrystal Pharma positions in Q2 2021 and 6 closed out, a net change of +7 holders.
- The largest Cocrystal Pharma buyer in Q2 2021 was Sabby Management, an estimated $7.74M added.
- The largest Cocrystal Pharma seller in Q2 2021 was Renaissance Technologies, an estimated $2.1M sold.
Based on aggregated 13F filings for Q2 2021.